These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31943623)

  • 41. Atypical case of discrete papular mucinosis involving acral and nuchal regions in an adult.
    Zeng YP; Ma DL
    J Dtsch Dermatol Ges; 2012 Apr; 10(4):266-7. PubMed ID: 22313743
    [No Abstract]   [Full Text] [Related]  

  • 42. Scleroderma-like acute renal crisis in a patient with scleromyxedema.
    Gwinner W; Erdbruegger U; Mengel M; Hafer C; Kittner J; Witte T; Voelker B; Haller H
    Nephrol Dial Transplant; 2007 Jul; 22(7):2063-7. PubMed ID: 17389621
    [No Abstract]   [Full Text] [Related]  

  • 43. Scleromyxedema.
    Cokonis Georgakis CD; Falasca G; Georgakis A; Heymann WR
    Clin Dermatol; 2006; 24(6):493-7. PubMed ID: 17113967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ineffectiveness of infliximab CT-P13 for the treatment of scleromyxedema: A case report.
    Arginelli F; Paganelli A; Rongioletti F; Pellacani G; Conti A
    Dermatol Ther; 2018 Mar; 31(2):e12583. PubMed ID: 29214719
    [No Abstract]   [Full Text] [Related]  

  • 45. Scleromyxedema Without Monoclonal Gammopathy Treated with Intravenous Immunoglobulins.
    Letzelter M; Grimaux X
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):51-53. PubMed ID: 34477065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unwelcomed face of scleromyxedema.
    Abdelmaksoud A
    Int J Dermatol; 2019 May; 58(5):e100-e102. PubMed ID: 30746691
    [No Abstract]   [Full Text] [Related]  

  • 47. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema.
    Bos R; de Waal EG; Kuiper H; Hazenberg BP; Vellenga E
    Rheumatology (Oxford); 2011 Oct; 50(10):1925-6. PubMed ID: 21719421
    [No Abstract]   [Full Text] [Related]  

  • 48. [Scleromyxedema].
    Kukova G; Bruch-Gerharz D; Gensch K; Ruzicka T; Reifenberger J
    Hautarzt; 2006 Apr; 57(4):326-7. PubMed ID: 16523272
    [No Abstract]   [Full Text] [Related]  

  • 49. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.
    Sroa N; Campbell S; Bechtel M
    J Drugs Dermatol; 2010 Mar; 9(3):263-5. PubMed ID: 20232589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Scleromyxedema treatment: a systematic review and update.
    Haber R; Bachour J; El Gemayel M
    Int J Dermatol; 2020 Oct; 59(10):1191-1201. PubMed ID: 32358980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rare scleromyxedema granuloma-annulare-like pattern successfully treated with intravenous immunoglobulins.
    Burzi L; Rosset F; Senetta R; Conti L; Mastorino L; Dapavo P; Quaglino P; Ribero S
    Ital J Dermatol Venerol; 2024 Feb; 159(1):80-81. PubMed ID: 38226941
    [No Abstract]   [Full Text] [Related]  

  • 52. Successful treatment of scleromyxedema with oral thalidomide.
    Guarenti I; Sebastiani V; Pinto G; de Souza PR; de Almeida H
    Int J Dermatol; 2013 May; 52(5):631-2. PubMed ID: 23231733
    [No Abstract]   [Full Text] [Related]  

  • 53. Acute Encephalitic Syndrome Induced by Scleromyxedema.
    Magira EE; Malouchou A; Karathanasi V; Mavropoulou N; Siempos II; Vourlakou C; Sykaras A; Anastasiadis G
    Am J Med Sci; 2020 Aug; 360(2):192-195. PubMed ID: 32540147
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interstitial Granulomatous Variant of Scleromyxedema-A Diagnostic Pitfall.
    Long V; Tan W; Lee SSJ; Thng TGS
    Am J Dermatopathol; 2018 Apr; 40(4):279-282. PubMed ID: 28961556
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term follow-up in a patient with the dermato-neuro syndrome treated with high-dose melphalan, thalidomide, and intravenous immunoglobulins for more than 7 years.
    Devos T; Thiessen S; Cuyle PJ; Meersseman W; Delforge M
    Ann Hematol; 2014 Nov; 93(11):1927-8. PubMed ID: 24676971
    [No Abstract]   [Full Text] [Related]  

  • 56. Atypical scleromyxedema with prominent nodular lesions associated with immune thrombocytopenia: an unusual presentation.
    Lopez-Lerma I; Fernandez-Codina A; Hilari H; Ferrer B; Selva-O'Callaghan A; Garcia-Patos V
    J Am Acad Dermatol; 2014 Oct; 71(4):e158-9. PubMed ID: 25219747
    [No Abstract]   [Full Text] [Related]  

  • 57. [Scleromyxedema].
    Neufeld M; Sunderkötter C; Moritz RKC
    Hautarzt; 2018 Nov; 69(11):916-921. PubMed ID: 30135969
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Monoclonal immunoglobulin (M-Ig) and skin diseases from the group of mucinoses--scleredema adultorum Buschke and scleromyxedema. Description of four cases and an overview of therapies].
    Adam Z; Szturz P; Krejčí M; Vašků V; Pour L; Michalková E; Ševčíková S; Čermáková Z; Veselý K; Vaníček J; Pourová E; Král Z; Mayer J
    Vnitr Lek; 2015 Dec; 61(12):1072-87. PubMed ID: 26806503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of intravenous immunoglobulins in severe scleromyxedema dysphagia assessed by oesophageal scintigraphy.
    Di Battista M; Grosso M; Marciano A; Scarpuzza M; Della Rossa A; Mosca M
    Clin Exp Rheumatol; 2024 Aug; 42(8):1706. PubMed ID: 39152750
    [No Abstract]   [Full Text] [Related]  

  • 60. [Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].
    Topf S; Simon M; Schell H; Lüftl M
    Hautarzt; 2007 Jun; 58(6):525-8. PubMed ID: 17165069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.